Who
Charles W. Newton
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Director, Novavax; Director, Coherus Oncology; Chief Financial Officer, Lyell Immunopharma; Director, 2seventy bio.
In numbers
- Trades disclosed
- 54
- Buys
- 1
- Sells
- 5
- Bought
- $112K
- Sold
- $40K
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 16 Mar 2022
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,675551 at $10.30 | filing |
| 18 Aug 2026filed 20 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,675551 at $10.30 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,522550 at $10.04 | filing |
| 11 Jun 2026filed 15 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,522550 at $10.04 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 Apr 2026filed 28 Apr 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —9,520 at $0.00 | filing |
| 25 Apr 2026filed 28 Apr 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,520 at $0.00 | filing |
| 25 Apr 2026filed 28 Apr 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,520 at $0.00 | filing |
| 25 Apr 2026filed 28 Apr 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —9,520 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,215 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,788 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,788 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,215 at $0.00 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)KROS · tickerreport.com · 24 Oct 2026Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)KROS · themarketsdaily.com · 24 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Charles W. Newton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.